Tags

Type your tag names separated by a space and hit enter

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.
JAMA Intern Med. 2020 Jul 21 [Online ahead of print]JIM

Abstract

Importance

Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected.

Objective

To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the US.

Design, Setting, and Participants

This cross-sectional study performed serologic testing on a convenience sample of residual sera obtained from persons of all ages. The serum was collected from March 23 through May 12, 2020, for routine clinical testing by 2 commercial laboratory companies. Sites of collection were San Francisco Bay area, California; Connecticut; south Florida; Louisiana; Minneapolis-St Paul-St Cloud metro area, Minnesota; Missouri; New York City metro area, New York; Philadelphia metro area, Pennsylvania; Utah; and western Washington State.

Exposures

Infection with SARS-CoV-2.

Main Outcomes and Measures

The presence of antibodies to SARS-CoV-2 spike protein was estimated using an enzyme-linked immunosorbent assay, and estimates were standardized to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). The number of infections in each site was estimated by extrapolating seroprevalence to site populations; estimated infections were compared with the number of reported coronavirus disease 2019 (COVID-19) cases as of last specimen collection date.

Results

Serum samples were tested from 16 025 persons, 8853 (55.2%) of whom were women; 1205 (7.5%) were 18 years or younger and 5845 (36.2%) were 65 years or older. Most specimens from each site had no evidence of antibodies to SARS-CoV-2. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein antibodies ranged from 1.0% in the San Francisco Bay area (collected April 23-27) to 6.9% of persons in New York City (collected March 23-April 1). The estimated number of infections ranged from 6 to 24 times the number of reported cases; for 7 sites (Connecticut, Florida, Louisiana, Missouri, New York City metro area, Utah, and western Washington State), an estimated greater than 10 times more SARS-CoV-2 infections occurred than the number of reported cases.

Conclusions and Relevance

During March to early May 2020, most persons in 10 diverse geographic sites in the US had not been infected with SARS-CoV-2 virus. The estimated number of infections, however, was much greater than the number of reported cases in all sites. The findings may reflect the number of persons who had mild or no illness or who did not seek medical care or undergo testing but who still may have contributed to ongoing virus transmission in the population.

Authors+Show Affiliations

CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.Florida Department of Health, Tallahassee.New York State Department of Health, Albany.Division of State and Local Readiness, Centers for Disease Control and Prevention, Atlanta, Georgia.Utah Department of Health, Salt Lake City.Louisiana Department of Health, New Orleans.California Department of Health, Richmond.Washington State Department of Health, Tumwater.Minnesota Department of Health, St Paul.Florida Department of Health, Tallahassee.Louisiana Department of Health, New Orleans.Connecticut Department of Public Health, Hartford.Missouri Department of Health and Senior Services, Jefferson City.Pennsylvania Department of Health, Harrisburg.Washington State Department of Health, Tumwater.Missouri Department of Health and Senior Services, Jefferson City.Minnesota Department of Health, St Paul.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32692365

Citation

Havers, Fiona P., et al. "Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020." JAMA Internal Medicine, 2020.
Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020.
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C. F., Gibbons, A., Krapiunaya, I., Morales-Betoulle, M., Roguski, K., Rasheed, M. A. U., Freeman, B., Lester, S., Mills, L., Carroll, D. S., Owen, S. M., ... Thornburg, N. J. (2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.4130
Havers FP, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020 Jul 21; PubMed PMID: 32692365.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. AU - Havers,Fiona P, AU - Reed,Carrie, AU - Lim,Travis, AU - Montgomery,Joel M, AU - Klena,John D, AU - Hall,Aron J, AU - Fry,Alicia M, AU - Cannon,Deborah L, AU - Chiang,Cheng-Feng, AU - Gibbons,Aridth, AU - Krapiunaya,Inna, AU - Morales-Betoulle,Maria, AU - Roguski,Katherine, AU - Rasheed,Mohammad Ata Ur, AU - Freeman,Brandi, AU - Lester,Sandra, AU - Mills,Lisa, AU - Carroll,Darin S, AU - Owen,S Michele, AU - Johnson,Jeffrey A, AU - Semenova,Vera, AU - Blackmore,Carina, AU - Blog,Debra, AU - Chai,Shua J, AU - Dunn,Angela, AU - Hand,Julie, AU - Jain,Seema, AU - Lindquist,Scott, AU - Lynfield,Ruth, AU - Pritchard,Scott, AU - Sokol,Theresa, AU - Sosa,Lynn, AU - Turabelidze,George, AU - Watkins,Sharon M, AU - Wiesman,John, AU - Williams,Randall W, AU - Yendell,Stephanie, AU - Schiffer,Jarad, AU - Thornburg,Natalie J, Y1 - 2020/07/21/ PY - 2020/7/22/entrez PY - 2020/7/22/pubmed PY - 2020/7/22/medline JF - JAMA internal medicine JO - JAMA Intern Med N2 - Importance: Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected. Objective: To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the US. Design, Setting, and Participants: This cross-sectional study performed serologic testing on a convenience sample of residual sera obtained from persons of all ages. The serum was collected from March 23 through May 12, 2020, for routine clinical testing by 2 commercial laboratory companies. Sites of collection were San Francisco Bay area, California; Connecticut; south Florida; Louisiana; Minneapolis-St Paul-St Cloud metro area, Minnesota; Missouri; New York City metro area, New York; Philadelphia metro area, Pennsylvania; Utah; and western Washington State. Exposures: Infection with SARS-CoV-2. Main Outcomes and Measures: The presence of antibodies to SARS-CoV-2 spike protein was estimated using an enzyme-linked immunosorbent assay, and estimates were standardized to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). The number of infections in each site was estimated by extrapolating seroprevalence to site populations; estimated infections were compared with the number of reported coronavirus disease 2019 (COVID-19) cases as of last specimen collection date. Results: Serum samples were tested from 16 025 persons, 8853 (55.2%) of whom were women; 1205 (7.5%) were 18 years or younger and 5845 (36.2%) were 65 years or older. Most specimens from each site had no evidence of antibodies to SARS-CoV-2. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein antibodies ranged from 1.0% in the San Francisco Bay area (collected April 23-27) to 6.9% of persons in New York City (collected March 23-April 1). The estimated number of infections ranged from 6 to 24 times the number of reported cases; for 7 sites (Connecticut, Florida, Louisiana, Missouri, New York City metro area, Utah, and western Washington State), an estimated greater than 10 times more SARS-CoV-2 infections occurred than the number of reported cases. Conclusions and Relevance: During March to early May 2020, most persons in 10 diverse geographic sites in the US had not been infected with SARS-CoV-2 virus. The estimated number of infections, however, was much greater than the number of reported cases in all sites. The findings may reflect the number of persons who had mild or no illness or who did not seek medical care or undergo testing but who still may have contributed to ongoing virus transmission in the population. SN - 2168-6114 UR - https://www.unboundmedicine.com/medline/citation/32692365/full_citation L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.4130 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.